Modulating the immune response to reduce hypertension-associated cardiovascular damage

J Clin Invest. 2022 Mar 15;132(6):e158280. doi: 10.1172/JCI158280.

Abstract

Cardiovascular diseases are a leading cause of mortality and disability worldwide. Hypertension, a major risk factor for these diseases, remains difficult to treat despite numerous drugs being available. In this issue of the JCI, Failer et al. show that the endogenous antiinflammatory agent developmental endothelial locus-1 (DEL-1) decreased blood pressure and cardiac and aortic hypertrophy in mouse models of hypertension through reduction in αvβ3 integrin-dependent metalloproteinase activity and immune cell recruitment, leading to reduced production of proinflammatory cytokines in cardiovascular tissues. This study offers an alternative in the treatment of hypertension-mediated organ damage through the immunomodulatory effect of DEL-1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Aorta
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Heart / physiopathology
  • Hypertension* / physiopathology
  • Immunity
  • Mice